Cargando…

Treatment of the antiphospholipid syndrome

The antiphospholipid syndrome is characterized by a combination of laboratory findings (i.e., the presence of at least one antiphospholipid antibody) and clinical manifestations (arterial and/or venous thrombosis, obstetrical complications). Long-term oral anticoagulant is recommended to prevent rec...

Descripción completa

Detalles Bibliográficos
Autor principal: Galli, Monica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4389011/
https://www.ncbi.nlm.nih.gov/pubmed/26000150
http://dx.doi.org/10.1007/s13317-013-0056-5
_version_ 1782365467919253504
author Galli, Monica
author_facet Galli, Monica
author_sort Galli, Monica
collection PubMed
description The antiphospholipid syndrome is characterized by a combination of laboratory findings (i.e., the presence of at least one antiphospholipid antibody) and clinical manifestations (arterial and/or venous thrombosis, obstetrical complications). Long-term oral anticoagulant is recommended to prevent recurrence of both arterial and venous thrombosis, whereas (low molecular weight) heparin plus aspirin is the treatment of choice to prevent further obstetrical complications. In the rare case of catastrophic antiphospholipid syndrome, heparin plus high-dose corticosteroids plus plasma exchange is associated with the highest recovery rate. Some new, non-antithrombotic-based treatments of antiphospholipid syndrome with rituximab, autologous stem cell transplantation, or hydroxychloroquine are also reviewed.
format Online
Article
Text
id pubmed-4389011
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-43890112015-05-21 Treatment of the antiphospholipid syndrome Galli, Monica Auto Immun Highlights Review Article The antiphospholipid syndrome is characterized by a combination of laboratory findings (i.e., the presence of at least one antiphospholipid antibody) and clinical manifestations (arterial and/or venous thrombosis, obstetrical complications). Long-term oral anticoagulant is recommended to prevent recurrence of both arterial and venous thrombosis, whereas (low molecular weight) heparin plus aspirin is the treatment of choice to prevent further obstetrical complications. In the rare case of catastrophic antiphospholipid syndrome, heparin plus high-dose corticosteroids plus plasma exchange is associated with the highest recovery rate. Some new, non-antithrombotic-based treatments of antiphospholipid syndrome with rituximab, autologous stem cell transplantation, or hydroxychloroquine are also reviewed. Springer International Publishing 2013-12-22 /pmc/articles/PMC4389011/ /pubmed/26000150 http://dx.doi.org/10.1007/s13317-013-0056-5 Text en © Springer-Verlag Italia 2013
spellingShingle Review Article
Galli, Monica
Treatment of the antiphospholipid syndrome
title Treatment of the antiphospholipid syndrome
title_full Treatment of the antiphospholipid syndrome
title_fullStr Treatment of the antiphospholipid syndrome
title_full_unstemmed Treatment of the antiphospholipid syndrome
title_short Treatment of the antiphospholipid syndrome
title_sort treatment of the antiphospholipid syndrome
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4389011/
https://www.ncbi.nlm.nih.gov/pubmed/26000150
http://dx.doi.org/10.1007/s13317-013-0056-5
work_keys_str_mv AT gallimonica treatmentoftheantiphospholipidsyndrome